| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 0.4 |
| Gross profit | -0.1 | -0.1 |
| Profit before tax | -2.6 | -2.3 |
| Net income | -2.6 | -2.3 |
| EPS (diluted, $ a share) | $-0.75 | $-2.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -46.7% |
|---|---|
| Gross margin | -41.8% |
10-Q filed with the SEC, NASDAQ: SXTP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
60 Degrees Pharmaceuticals, Inc.: key numbers
- Share price
- $0.4938Close, Nov 16
- Market cap
- $2.21M
- Shares outstanding
- 4.48MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from 60 Degrees Pharmaceuticals, Inc.
All →60 Degrees Pharmaceuticals Capital Raise of $526K
60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.
- Value
- $526K
60 Degrees Pharmaceuticals Clinical Trial Data
60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.
60 Degrees Pharmaceuticals Investor Presentation
60 Degrees Pharmaceuticals updated its investor presentation for use in meetings with investors and analysts, specifically highlighting progress for Tafenoquine in treating Babesiosis. The presentation was featured at the 2026 ILADS Annual Scientific Conference and outlines a regulatory objective for a potential sNDA submission in 2027.
60 Degrees Pharmaceuticals Investor Presentation
60 Degrees Pharmaceuticals updated its investor presentation and held a webinar to discuss interim data from its clinical study of tafenoquine for severe babesiosis. The presentation covers clinical context, DSMB feedback from the hospital study, and the regulatory path forward for the treatment.
60 Degrees Pharmaceuticals Business Update
60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher (CNPV) for its ARAKODA (tafenoquine) efficacy supplement for babesiosis. The company aims to submit a supplemental New Drug Application (sNDA) in early 2027, potentially making it the first FDA-approved treatment for the tick-borne disease. An interim analysis of its randomized controlled trial is scheduled for October 1, 2026.
- Counterparty
- FDA